Forced degradation of tacrolimus and the development of a UHPLC method for impurities determination

1. T. Kino, H. Hatanaka, M. Hashimoto, M. Nishiyama, T. Goto, M. Okuhara, M. Kohsaka, H. Aoki and H. Imanaka, FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics, J. Antibiot.40 (1987) 1249–1255; https://doi.org/10.7164/antibiotics.40.124910.7164/antibiotics.40.1249Search in Google Scholar

2. T. Kino, H. Hatanaka, S. Miyata, N. Inamura, M. Nishiyama, T. Yajima, T. Goto, M. Okuhara, M. Kohsaka, H. Aoki and T. Ochia, FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro, J. Antibiot.40 (1987) 1256–1265; https://doi.org/10.7164/antibiotics.40.125610.7164/antibiotics.40.1256Search in Google Scholar

3. T. Goto, T. Kino, H. Hatanaka, M. Nishiyama, M. Okuhara, M. Kohsaka, H. Aoki and H. Imanaka, Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis, Transplant. Proc.19 (1987) 4–8.Search in Google Scholar

4. J. J. Fung, Tacrolimus and transplantation: a decade in review, Transplantation77 (2004) S41-S43; https://doi.org/10.1097/01.TP.0000126926.61434.A510.1097/01.TP.0000126926.61434.A5Search in Google Scholar

5. M. R. First, Tacrolimus based immunosuppression, J. Nephrol.17 (2004) S25–S31.Search in Google Scholar

6. D. Simpson and S. Noble, Tacrolimus ointment – A review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions, Drugs65 (2005) 827–858; https://doi.org/10.2165/00003495-200565060-0001110.2165/00003495-200565060-00011Search in Google Scholar

7. S. Dutta and Y. Ahmad, The efficacy and safety of tacrolimus in rheumatoid arthritis, Ther. Adv. Musculoskelet. Dis.3 (2011) 283–291; https://doi.org/10.1177/1759720X1141903810.1177/1759720X11419038Search in Google Scholar

8. D. M. Skytte, J. W. Jaroszewski, K. T. Johansen, S. H. Hansen, L. Hansen, P. G. Nielsen and K. Frydenvang, Some transformations of tacrolimus, an immunosuppressive drug, Eur. J. Pharm. Sci.48 (2013) 514–522; https://doi.org/10.1016/j.ejps.2012.12.00110.1016/j.ejps.2012.12.001Search in Google Scholar

9. H. Ok, B. H. Arison, R. G. Ball, T. R. Beattie, M. H. Fisher and M. J. Wyvratt, Thermal rearrangement of the immunosuppressant FK-506, Tetrahedron Lett.31 (1990) 6477–6480; https://doi.org/10.1016/S0040-4039(00)97095-310.1016/S0040-4039(00)97095-3Search in Google Scholar

10. D. M. Skytte, K. Frydenvang, L. Hansen, P. G. Nielsen and J. W. Jaroszewski, Synthesis and characterization of an epimer of tacrolimus, an immunosuppressive drug, J. Nat. Prod.73 (2010) 776–779; https://doi.org/10.1021/Np900797510.1021/np900797520166703Search in Google Scholar

11. P. Ferraboschi, D. Colombo, M. De Mieri and P. Grisenti, Evaluation, synthesis and characterization of tacrolimus impurities, J. Antibiot.65 (2012) 349–354; https://doi.org/10.1038/Ja.2012.2810.1038/ja.2012.2822511227Search in Google Scholar

12. C. D. Sommers, E. S. Pang, H. Ghasriani, R. T. Berendt, V. L. Vilker, D. A. Keire and M. T. Boyne, 2nd, Analyses of marketplace tacrolimus drug product quality: bioactivity, NMR and LC-MS, J. Pharm. Biomed. Anal.85 (2013) 108–117; https://doi.org/10.1016/j.jpba.2013.07.00110.1016/j.jpba.2013.07.00123917038Search in Google Scholar

13. T. Rozman Peterka, R. Grahek, J. Hren, A. Bastarda, J. Bergles and U. Urleb, Solid state compatibility study and characterization of a novel degradation product of tacrolimus in formulation, J. Pharm. Biomed. Anal.110 (2015) 67–75; https://doi.org/10.1016/j.jpba.2015.02.04710.1016/j.jpba.2015.02.047Search in Google Scholar

14. United State Pharmacopeia 41, National Formulary 36, US Pharmacopeial Convention, Rockville 2018, pp. 3906–3914; https://online.uspnf.com/uspnf; last access date December 24, 2018.Search in Google Scholar

15. European Pharmacopoeia 9.3, Council of Europe, Strasbourg 2018, pp. 4997–4999; http://online6.edqm.eu/ep905/; last access date December 24, 2018.Search in Google Scholar

16. T. Akashi, T. Nefuji, M. Yoshida and J. Hosoda, Quantitative determination of tautomeric FK506 by reversed-phase liquid chromatography, J. Pharm. Biomed. Anal.14 (1996) 339–346; https://doi.org/10.1016/0731-7085(95)01605-810.1016/0731-7085(95)01605-8Search in Google Scholar

17. Y. Namiki, N. Kihara, S. Koda, K. Hane and T. Yasuda, Tautomeric phenomenon of a novel potent immunosuppressant (FK506) in solution I. Isolation and structure determination of tautomeric compounds, J. Antibiot.46 (1993) 1149–1155; https://doi.org/10.7164/antibiotics.46.114910.7164/antibiotics.46.11497689551Search in Google Scholar

18. Y. Namiki, A. Fujiwara, N. Kihara, S. Koda, K. Hane and T. Yasuda, Determination of the immunosuppressive drug tacrolimus in its dosage forms by high-performance liquid-chromatography, Chromatographia40 (1995) 253–258; https://doi.org/10.1007/Bf0229035410.1007/BF02290354Search in Google Scholar

19. Q. Shi, J. Li and F. Ding, Development and validation of method for the determination of related substances of tacrolimus in tacrolimus capsules and degradation studies, Int. J. ChemTech Res.4 (2012) 1543–1552.Search in Google Scholar

20. A. Subasranjan, C. Srinivasulu and R. Hemant, An improved validated ultra high pressure liquid chromatography method for separation of tacrolimus impurities and its tautomers, Drug Test. Anal.2 (2010) 107–112; https://doi.org/10.1002/dta.11210.1002/dta.11220878891Search in Google Scholar

21. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1), Current Step 4 version, October 1994 (parent), November 1996 (complementary); http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf; last access date September 19, 2018.Search in Google Scholar

22. N. S. Trasi, H. S. Purohit and L. S. Taylor, Evaluation of the crystallization tendency of commercially available amorphous tacrolimus formulations exposed to different stress conditions, Pharm. Res.34 (2017) 2142–2155; https://doi.org/10.1007/s11095-017-2221-410.1007/s11095-017-2221-428687987Search in Google Scholar